Investors Urged to Join Soleno Therapeutics Securities Fraud Lawsuit Lead

Important Investor Notice: Soleno Therapeutics Class Action

The Rosen Law Firm, a well-known legal entity focusing on investor rights, has issued an urgent notice regarding potential securities fraud involving Soleno Therapeutics, Inc. With the lead plaintiff deadline set for May 5, 2026, affected investors are encouraged to take proactive steps to join the class action lawsuit.

Overview of the Situation

For those who purchased common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, you may be eligible for compensation in this class action lawsuit without incurring any out-of-pocket costs due to a contingency fee arrangement. If you fit this profile, acting soon is crucial.

How to Participate

To join the class action, interested parties can visit Rosen Law Firm's website or contact attorney Phillip Kim via phone at 866-767-3653 or email at [email protected]. It is important to note that a class action lawsuit has already been initiated, and prompt action is required for those wishing to serve as lead plaintiff, which represents other members of the class during the proceedings.

Why Choose Rosen Law Firm?

Rosen Law Firm has a noteworthy reputation as a distinguished advocate for investors. They emphasize the necessity of engaging qualified legal counsel with a proven success record in handling securities class actions. Unlike other firms that may simply act as intermediaries, Rosen Law Firm has a history of serious litigation and has secured substantial settlements for investors. For instance, the firm achieved the largest securities class action settlement against a Chinese company and has consistently ranked among the highest in the industry.

Details of the Allegations

The foundation of the lawsuit lies in claims that Soleno Therapeutics made misleading statements and failed to disclose critical safety concerns related to its drug—DCCR (diazoxide choline extended-release tablets). Allegations include that Soleno downplayed significant evidence of safety issues, including potential risks of excess fluid retention tied to the medication, which could severely impact its commercial viability. These misrepresentations left investors unaware of the real risks associated with DCCR, leading to unexpected damages upon the revelation of the truth in the market.

Call to Action

If you are an investor who purchased Soleno common stock during the specified class period and is interested in participating in this class action, immediate action is necessary. You can either join the lawsuit through the provided link or reach out directly to Rosen Law Firm for additional information. Remember, until the class is officially certified, investors are not represented unless they are signed on with a legal counsel.

Stay informed by following Rosen Law Firm on LinkedIn, Twitter, or Facebook for future updates.

Important Notes

Remember, participating in this class action does not cost anything upfront, and the pathway to recovery does not require the investor to take on the financial burden. Acting swiftly is essential as the deadline of May 5, 2026, is fast approaching for those wanting to lead the charge against Soleno Therapeutics. For legal counsel of your choice, stay informed, and make decisions that align with your interests as a shareholder.